Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

被引：0
|
作者：
Kulasekararaj, Austin G. [1 ]
Mohamedali, Azim M. [2 ]
Smith, Alexander E. [2 ]
Lea, Nicholas C. [2 ]
Kizilors, Aytug [2 ]
Abdallah, Atiyeh [1 ]
Nasser, Erik E. [2 ]
Mian, Syed A. [2 ]
Yiu, Richard [1 ]
Gaken, Joop [2 ]
Pomplun, Sabine [2 ]
Jiang, Jie [1 ]
Gaymes, Terry J. [2 ]
Pasipanodya, Patience [1 ]
Hayden, Janet [1 ]
Ireland, Robin M. [1 ]
Lim, ZiYi [1 ]
Ho, Aloysius Y. [1 ]
Marsh, Judith C. W. [1 ]
Mufti, Ghulam J. [2 ]
机构：
[1] Kings Coll Hosp, Dept Haematol Med, London, England
[2] Kings Coll London, Dept Haematol Med, London WC2R 2LS, England
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [11] Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine
    Radsak, Markus
    Platzbecker, Uwe
    Schmidt, Cornelia S.
    Hofmann, Wolf-Karsten
    Nolte, Florian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (02) : 112 - 118
  • [12] The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group
    Papageorgiou, Sotirios G.
    Vasilatou, Diamantina
    Kontos, Christos K.
    Kotsianidis, Ioannis
    Symeonidis, Argiris
    Galanopoulos, Athanasios G.
    Hatzimichael, Eleftheria
    Megalakaki, Aekaterini
    Poulakidas, Elias
    Diamantopoulos, Panagiotis
    Vassilakopoulos, Theodoros P.
    Zikos, Panagiotis
    Papadaki, Helen
    Mparmparousi, Despoina
    Bouronikou, Eleni
    Panayiotidis, Panayiotis
    Viniou, Nora-Athina
    Pappa, Vassiliki
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (07) : 895 - 901
  • [13] EXPERIENCE WITH 5-AZACITIDINE (AZA) IN MYELOPROLIFERATIVE MYELODYSPLASTIC SYNDROME (SMD/MP)
    Javier Gonzalez, K. P.
    Ortiz, S.
    Villegas, C.
    Orero, M. T.
    Collado, R.
    Roig, M.
    Perez, P.
    Luna, I
    Ivars, D.
    Linares, M.
    Lopez, M.
    HAEMATOLOGICA, 2015, 100 : 257 - 257
  • [14] FLOW CYTOMETRY PREDICTS TREATMENT OUTCOME IN INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH 5-AZACITIDINE
    Alhan, C.
    Westers, T.
    Cali, C.
    Eeltink, C.
    Ossenkoppele, G.
    van de Loosdrecht, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 379 - 380
  • [15] Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy
    Kaur, Jaspreet
    Tuler, Shahaf
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (07) : 1775 - 1778
  • [16] Late Hematological Improvement of Myelodysplastic Syndrome Following Treatment with 5-Azacitidine Therapy
    Takaoka, Kensuke
    Hangaishi, Akira
    Ito, Ayumu
    Morioka, Takehiko
    Kida, Michiko
    Usuki, Kensuke
    INTERNAL MEDICINE, 2014, 53 (19) : 2241 - 2243
  • [17] Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
    Hwang, Kyung-Lim
    Song, Moo-Kon
    Shin, Jin
    Na, Hae-Jung
    Shin, Dong-Hun
    Kim, Joong-Keun
    Moon, Joon-Ho
    Ahn, Jae-Sook
    Song, Ik-Chan
    Hong, Junshik
    Lee, Gyeong-won
    Chung, Joo-Seop
    BLOOD RESEARCH, 2014, 49 (04) : 234 - 240
  • [18] Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
    Kobayashi, Yukio
    Munakata, Wataru
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Kobayashi, Tsutomu
    Shimada, Fumika
    Yonemura, Masataka
    Matsuoka, Fumiko
    Tajima, Takeshi
    Yakushijin, Kimikazu
    Minami, Hironobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (01) : 83 - 91
  • [19] Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia
    Yukio Kobayashi
    Wataru Munakata
    Michinori Ogura
    Toshiki Uchida
    Masafumi Taniwaki
    Tsutomu Kobayashi
    Fumika Shimada
    Masataka Yonemura
    Fumiko Matsuoka
    Takeshi Tajima
    Kimikazu Yakushijin
    Hironobu Minami
    International Journal of Hematology, 2018, 107 : 83 - 91
  • [20] Comparison of the IPSS and IPSS-R in Predicting Survival and Response of Myelodysplastic Syndrome Patients to 5-Azacitidine
    Shapiro, Roman M.
    Lazo-Langner, Alejandro
    BLOOD, 2016, 128 (22)
12345